Rosalind Franklin Society Proudly Announces the 2023 Award Recipient for Human Gene Therapy

Dr. Gloria Gonzalez Aseguinolaza has been a leading gene therapy scientist and author of numerous contributions to Human Gene Therapy and other leading gene therapy journals for many years. Her work has mostly focused on the interface between adeno-associated virus (AAV) gene therapy and the immune system, although she has also made major contributions to the field of liver-directed AAV gene therapy for a wide range of genetic disorders. Her work has shed light on the choice of AAV serotypes for treating various diseases. It has directly advanced the body of knowledge enabling gene therapy clinical trialists to manage the immune response to AAV vectors more effectively. As a visible leader of both the Spanish Society of Gene Therapy and the European Society of Gene Therapy, she has been an exemplary role model for younger scientists striving to establish their careers in this field.

Biosketch

Gloria González-Aseguinolaza, PhD, is the director of the Gene Therapy for rare diseases and associate professor at CIMA Universidad de Navarra. Co-founder and CSO of the French biotech company Vivet Therapeutics, Dr. González-Aseguinolaza is a renowned researcher with extensive experience in the field of gene therapy. Her contributions to the field have been published in 137 top peer-reviewed and specialized journals. She was the President of the Spanish Society for Gene and Cell Therapy from 2019 until 2023 and is currently the secretary of the ESGCT. She has participated in the organization of both National and European Gene and Cell Therapy annual meetings and educational activities. She has trained 22 PhD and more than 30 national and foreign undergraduate, graduate and master students.